Trial Profile
Phase II Trial of Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Chinese Patients With Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2018
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 22 Dec 2017 Status changed from recruiting to completed, according to the results published in the BMC Cancer
- 16 May 2014 New trial record